Edited by

Vandana B. Patravale,PhD, is a professor of pharmaceutics at Department of Pharmaceutical Sciences and Technology of the Institute of Chemical Technology in India. She has written over 90 refereed publications and seven book chapters and has been granted three patents with another 24 patents in the pipeline and 3 trademark registries to her credit. Dr. Patravale has worked on various industrial, national and international projects throughout her career and has known expertise in the area of pharmaceutics. Her areas of expertise include conventional and modified release dosage forms, medical device development viz. coronary stents, intrauterine devices, nanodiagnostics, novel nanocarriers with major emphasis on malaria, cancer and neurodegenerative disorders, and formulation strategies to enhance bioavailability and/or targeting.

John I. Disouza

, PhD, is a professor in pharmaceutics and principal at Tatyasaheb Kore College of Pharmacy in Warananagar, India. He has over 15 years of teaching and research experience. He also has an executive MBA (Higher education) degree. Dr. Disouza has written two books and published over 50 research papers in peer reviewed journals. He has worked in diverse research areas including herbal formulations, micro/nanoparticulate, self-emulsifying, liposomal, fast and modified release drug delivery systems. His areas of interest include probiotics, novel diagnostic tools and therapies in cancer, and structural modifications of natural polymers for their pharmaceutical potential. He is an active consultant to pharmaceutical industry.

Mrs. Maharukh Rustomjee

is the founder, director, and chief operating officer of Rubicon Research Pvt. Limited and serves on the Board of Directors for the company. She has 30 years of experience in the dosage form development and drug delivery platform technologies in all phases of product development from product design through commercial manufacturing. She has spearheaded Rubicon's drug delivery technology effort, built a strong Intellectual Property knowledge base, developed complex generics, worked on FTF opportunities for leading generics, and worked on LCM opportunities with Innovator Pharma companies. She is the holder of numerous patents in the area of drug delivery systems.